The global rosacea treatment market size reached US$ 1.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.6 Billion by 2028, exhibiting a growth rate (CAGR) of 6.1% during 2023-2028.
Rosacea treatment refers to preventive measures adopted to cure a chronic skin disease that enlarges blood vessels and causes redness. It includes oral and topical medications, such as antibiotics, alpha agonists, retinoids, corticosteroids, immunosuppressants, and antihypertensive agents. In severe cases, intense pulsed light therapy, laser treatment, and cosmetic surgery are used to remove thickened skin, shrink tissues, and treat rhinophyma. Rosacea treatment assists in easing the symptoms, such as skin inflammation, redness, inflamed eyes, and puss-filled bumps that generally occur on the nose, cheeks, chest, ear, back, and forehead. It also reduces skin discoloration and improves dryness, itching, blurred vision, and sensitivity to light.
Rosacea Treatment Market Trends:
The increasing prevalence of rosacea due to excessive temperature changes, exercise, rising application of cosmetics, pharmaceuticals, and widespread consumption of spicy meals, hot drinks, and alcohol is one of the key factors driving the market growth. Furthermore, increasing demand for oral treatments, such as syrups, tablets, capsules, and liquids, to reduce redness, acne, pimples, and bacterial inflammation, is providing a considerable boost to the market growth. Additionally, the introduction of artificial intelligence (AI)-powered diagnostic tools that utilize digital image shots in natural white light and resolutions to identify facial lesions and symptoms and recognize areas prone to rosacea is creating a positive outlook for the market. Moreover, increasing adoption of combination treatments to reduce initial prominent symptoms, prevent relapse on discontinuation of oral therapy, and maintain long-term control is providing an impetus to the market growth. Other factors, including increasing initiatives and investments by several governments to promote research and development (R&D) activities, rising expenditure capacities of consumers, the launch of new generic products by pharmaceutical companies to increase the efficiency of the treatment, and growing awareness of early diagnosis and effective treatment options, are anticipated to drive market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global rosacea treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, drug class, route of administration, distribution channel and end user.
Breakup by Type:
- Erythematotelangiectatic Rosacea
- Papulopustular Rosacea
- Ocular Rosacea
- Phymatous Rosacea
Breakup by Drug Class:
- Alpha Agonists
- Antihypertensive Agents
Breakup by Route of Administration:
Breakup by Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Breakup by End User:
- Specialty Clinics
Breakup by Region:
- North America
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bausch Health Companies Inc., Cellix Bio Private Limited, Colorescience Inc., Croda International Plc, Galderma S.A., LEO Pharma A/S, Lupin Limited, Maruho Co. Ltd., PruGen Pharmaceuticals, Sol-Gel Technologies Ltd. and Timber Pharmaceuticals LLC.
|Base Year of the Analysis
||Type, Drug Class, Route of Administration, Distribution Channel, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Bausch Health Companies Inc., Cellix Bio Private Limited, Colorescience Inc., Croda International Plc, Galderma S.A., LEO Pharma A/S, Lupin Limited, Maruho Co. Ltd., PruGen Pharmaceuticals, Sol-Gel Technologies Ltd. and Timber Pharmaceuticals LLC.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)